Bristol-Myers Squibb Reports 6% Revenue Growth to $12.973 Billion in Q2 2026

Bristol-Myers Squibb Company (BMS) reported its financial results for the second quarter of 2026, revealing total revenues of $12.973 billion, a 6% increase from $12.269 billion in the same period last year. For the first half of 2026, revenues reached $24.462 billion, up 4% from $23.470 billion in the prior year. The company's net earnings attributable to BMS were $3.317 billion for the second quarter, compared to $1.310 billion in 2025, while year-to-date net earnings rose to $5.994 billion from $3.766 billion. The diluted earnings per share (EPS) for the quarter was $1.62, significantly higher than $0.64 in the previous year.

The financial performance was bolstered by increased demand and higher average net selling prices across its Growth Portfolio, particularly for the drug Eliquis, which saw a 22% revenue increase in the second quarter. However, this growth was partially offset by the impact of generics on the Legacy Portfolio, which experienced a decline in revenues. The company noted a significant reduction in gross-to-net (GTN) adjustments, which fell by 46% in the second quarter, contributing to the overall revenue increase.

Strategically, BMS has made notable advancements in its product pipeline, including the FDA's acceptance of new drug applications for iberdomide and mezigdomide, with respective PDUFA dates set for August 17, 2026, and May 13, 2027. The company also entered into a global strategic collaboration with Hengrui to develop 13 early-stage assets in oncology, hematology, and immunology, further enhancing its research and development capabilities. Additionally, BMS has been actively managing its operational structure through a restructuring plan aimed at achieving approximately $2 billion in annual cost savings by the end of 2027.

Operationally, BMS reported a decrease in cash and cash equivalents to $8.722 billion as of June 30, 2026, down from $10.209 billion at the end of 2025. The company’s total assets decreased to $87.634 billion from $90.038 billion, while total liabilities also declined to $65.315 billion from $71.533 billion. The company’s employee headcount remained stable, reflecting its commitment to maintaining operational efficiency amid ongoing strategic initiatives.

Looking ahead, BMS anticipates continued growth driven by its innovative product pipeline and strategic collaborations. However, the company remains cautious about potential regulatory pressures and market conditions that could impact pricing and reimbursement rates. The ongoing implementation of the Inflation Reduction Act (IRA) and its implications for drug pricing will be closely monitored as BMS navigates its future financial landscape.